Drug Search Results
More Filters [+]

YJP-14

Alternative Names: yjp-14, yjp14, yjp 14
Latest Update: 2016-08-17
Latest Update Note: Clinical Trial Update

Product Description

for the treatment of endothelial dysfunction in patients with diabetes mellitus; An 50% ethanolic extract of Lindera obtusiloba stems (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01836172)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Han Wha Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for YJP-14

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Diabetes Complications

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HW2012-YJP002

P2

Unknown status

Diabetes Complications

2016-12-01

Recent News Events

Date

Type

Title